FISHMAN BARRY 4

What Happened Barry Fishman, a director of Medicus Pharma Ltd. (MDCX), was granted a derivative award (option) to acquire 50,000 shares on June 3, 2026. The Form 4 reports an acquisition of 50,000 shares at $0.00 (derivative instrument), with a $0 total value shown on the filing. This is a compensation-style award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-04 (timely filing).
• Transaction type/code: A (Grant/Award — derivative).
• Amount: 50,000 shares (derivative option reported at $0.00).
• Vesting: Option vests quarterly in four equal installments over one year (per footnote F1).
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• No immediate sale or cashless exercise reported.

Context This is a typical equity compensation grant to an insider (director). It does not represent an open-market purchase (which some investors view as a stronger bullish signal) nor a sale. The award vests over one year, so future reported transactions could occur as portions vest or are exercised.